Marinus Pharmaceuticals (NASDAQ:MRNS) Coverage Initiated by Analysts at StockNews.com

Stock analysts at StockNews.com assumed coverage on shares of Marinus Pharmaceuticals (NASDAQ:MRNS) in a research note issued on Tuesday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

Marinus Pharmaceuticals Stock Down 0.2 %

NASDAQ MRNS opened at $0.55 on Tuesday. The firm has a 50-day moving average price of $0.55 and a two-hundred day moving average price of $0.76. Marinus Pharmaceuticals has a 12-month low of $0.22 and a 12-month high of $9.69. The company has a market capitalization of $30.32 million, a P/E ratio of -0.22 and a beta of 1.03.

Institutional Investors Weigh In On Marinus Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in the stock. Woodline Partners LP raised its holdings in Marinus Pharmaceuticals by 84.7% in the 4th quarter. Woodline Partners LP now owns 2,335,681 shares of the biopharmaceutical company’s stock valued at $1,250,000 after acquiring an additional 1,071,410 shares in the last quarter. Beryl Capital Management LLC acquired a new position in Marinus Pharmaceuticals in the fourth quarter valued at about $2,262,000. GABELLI & Co INVESTMENT ADVISERS INC. bought a new stake in Marinus Pharmaceuticals during the fourth quarter worth about $54,000. XTX Topco Ltd grew its stake in Marinus Pharmaceuticals by 1,564.7% during the fourth quarter. XTX Topco Ltd now owns 219,819 shares of the biopharmaceutical company’s stock worth $118,000 after buying an additional 206,614 shares in the last quarter. Finally, JPMorgan Chase & Co. increased its holdings in Marinus Pharmaceuticals by 266.1% in the 4th quarter. JPMorgan Chase & Co. now owns 487,584 shares of the biopharmaceutical company’s stock valued at $261,000 after buying an additional 354,393 shares during the period. Institutional investors and hedge funds own 98.80% of the company’s stock.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.